Evidence map›Paper›PMID 27637206›Full record

ArticleWiener klinische Wochenschrift2017

Prognostic nutritional index as a predictor of prognosis in patients with diffuse large B cell lymphoma.

Vlatka Periša, Lada Zibar, Ana Knezović, Igor Periša, Jasminka Sinčić-Petričević, Igor Aurer

Abstract read
PubMed Publisher
In one paragraph

Article in Wiener klinische Wochenschrift, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Observational
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Vlatka PerišaDepartment of Hematology, Clinic of Internal Medicine, Osijek University Hospital, Josipa Huttlera 4, HR-31000, Osijek, Croatia. vlatkaperisa@gmail.com.
Lada ZibarDepartment for Pathophysiology, Faculty of Medicine, University of Osijek, Josipa Huttlera 4, HR-31000, Osijek, Croatia.
Ana KnezovićCommunity Health Centre Đakovo, P. Preradovića 2, HR-31400, Đakovo, Croatia.
Igor PerišaCommunity Health Centre Vinkovci, Ul. kralja Zvonimira 53, HR-32100, Vinkovci, Croatia.
Jasminka Sinčić-PetričevićDepartment of Hematology, Clinic of Internal Medicine, Osijek University Hospital, Josipa Huttlera 4, HR-31000, Osijek, Croatia.
Igor AurerDivision of Hematology, Department of Internal Medicine, University Hospital Centre Zagreb and School of Medicine, University of Zagreb, Kišpatićeva 12, HR-10000, Zagreb, Croatia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognostic nutritional index (PNI), an indicator of nutritional status and systemic inflammation, is associated with short-term and long-term outcomes of various malignancies. The prognostic value of PNI in diffuse large B cell lymphoma (DLBCL) remains unknown. The aim of the present study was to determine the prognostic value of baseline PNI in DLBCL patients.

methodsWe retrospectively analyzed data from 103 DLBCL patients treated with R‑CHOP or R‑CHOP-like regimens. We evaluated the significance of PNI as a predictor of response to treatment, overall survival (OS) and event-free survival (EFS).

resultsPatients with a PNI ≤ 44.55, where the cut-off was calculated by receiver operating characteristics (Youden index) and the same was obtained for response to treatment with 76.2 % sensitivity and a specificity of 85.4 %, for OS with 72.4 % sensitivity and a specificity of 90.5 % and for EFS with 65.6 % sensitivity and a specificity of 90.1 %, had significantly worse 5‑year OS (18.3 % vs 86.4 %, P < 0.001, log rank test) and 5‑year EFS (15.1 % vs 82.3 %, P < 0.001, log rank test). Regression analysis showed that PNI ≤ 44.55 was an independent prognostic factor for response to treatment with an odds ratio (OR) of 4.88 for treatment failure, 95 % confidence interval (CI) 1.077-22.105, OS hazard ratio (HR) 4.24, 95 % CI 1.451-12.392 and EFS HR 4.007, 95 % CI 1.48-10.852. Lower PNI levels were found in patients with advanced Ann Arbor clinical stage (46.6 ± 7.77 vs. 52.7 ± 5.43) and in those with poor response to therapy (40.58 ± 7.26 vs. 50.67 ± 6.26).

conclusionsThe PNI is a simple and useful marker to predict long-term survival outcome in DLBCL patients. Low PNI predicted poor outcome. A limitation of the study is its retrospective design in which the prognostic value was tested in the derivation cohort only. Notwithstanding, this is the first study suggesting that PNI is an important prognostic factor in DLBCL.

Indexed as

Nutritional StatusNutrition AssessmentAntineoplastic Combined Chemotherapy ProtocolsCausalityComorbidityCroatiaCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleHumansLymphoma, B-CellMaleNutrition DisordersPrednisonePrevalenceCyclophosphamideDoxorubicinPrednisoneVincristineLymphoma, large B-cell, diffusePrognosisPrognostic markerPrognostic nutritional index

Identifiers

PMID27637206

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.